FHA
TEVA icon

Flagship Harbor Advisors’s Teva Pharmaceuticals TEVA Stock Holding History

Flagship Harbor Advisors’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-3,014
Closed -$94.1K – 2037
2025
Q4 		$94.1K Buy
+3,014
New +$74.3K ﹤0.01% 885
2024
Q4 		– Sell
-10,629
Closed -$192K – 787
2024
Q3 		$192K Buy
+10,629
New +$186K 0.01% 700
2020
Q4 		– Sell
-2,671
Closed -$24K – 1635
2020
Q3 		$24K Buy
2,671
+2,344
+717% +$24.8K ﹤0.01% 1092
2020
Q2 		$4K Hold
327
– – ﹤0.01% 1667
2020
Q1 		$3K Buy
327
+100
+44% +$1.02K ﹤0.01% 1578
2019
Q4 		$2K Hold
227
– – ﹤0.01% 1739
2019
Q3 		$1K Hold
227
– – ﹤0.01% 1784
2019
Q2 		$2K Hold
227
– – ﹤0.01% 1711
2019
Q1 		$3K Buy
227
+60
+36% +$1.06K ﹤0.01% 1622
2018
Q4 		$2K Sell
167
-200
-54% -$4.1K ﹤0.01% 1671
2018
Q3 		$8K Sell
367
-408
-53% -$9.47K ﹤0.01% 1546
2018
Q2 		$18K Buy
+775
New +$15.8K ﹤0.01% 1150

Other funds holding TEVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return
WCM Investment Management
WCM Investment Management Laguna Beach, California $55.2B AUM 57.07% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Flagship Harbor Advisors's TEVA Position: Q1 2026 in Review

Flagship Harbor Advisors sold out of Teva Pharmaceuticals (TEVA) in Q1 2026, closing a stake of 3,014 shares — an estimated $94.1K sold.

Flagship Harbor Advisors first reported a position in TEVA in Q2 2018 and held it in 12 quarters. The position peaked at $192K in Q3 2024. 651 funds tracked by Wall St. Rank hold TEVA as of Q1 2026.

  • Flagship Harbor Advisors reported no remaining Teva Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Flagship Harbor Advisors sold 3,014 Teva Pharmaceuticals shares in Q1 2026, an estimated $94.1K.
  • Flagship Harbor Advisors first reported a position in Teva Pharmaceuticals in Q2 2018 and held it in 12 quarters.
  • Flagship Harbor Advisors's Teva Pharmaceuticals position peaked at $192K in Q3 2024.
  • 651 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2026.

Based on Flagship Harbor Advisors's 13F filing for Q1 2026, filed 28 Apr 2026.